Every gene tells a story

Delivering a future of health for all

Every gene tells a story

Delivering a future of health for all

Genomic medicine has the potential to transform patients’ lives. At Nanotransfer our mission is to reimagine the future of gene therapy by unlocking its full potential.

Globally, there are 500 million people affected by genetic diseases.
That is 1 in every 15 people.

Gene therapies are the definitive cure for genetic based diseases. However, there are approximately 50 FDA approved therapies out of 10000 reported genetic diseases. It has been challenging to produce the appropriate vehicle to deliver functional genes into damaged cells.

Nanotransfer is a game changer for gene therapies since allow the unleash next generation therapy will positively impact people’s life quality as well as allowing all patients to access this treatment.

We develop our own library of non-viral, safe, efficient, and cost-effective delivery system for gene therapy applications.
At Nanotransfer we have the key to unlocking the potential of gene therapies.

We are a Science-Driven Nanobiotech Company

In Nanotransfer we are developing a cutting edge library of nanoparticles based on metal oxides that can deliver genes in-vitro, ex-vivo and in-vivo gene therapies. We have the knowledge to target specific tissues by tuning the properties of synthesized nanoparticles. Our vehicles are agnostic: they can deliver different kinds of nucleic acid and sophisticated editing tools such as CRISPR.

Our system is:

Ready-to-use

Accessible to all patients

Re-treatment possibility

Extensive payload

Cell targeting

Our system is agnostic

Nanotransfer workflow

Gene production

Our customers focus on gene design to cure a specific disease.

Vehicle selection

Based on gene size and target cell, customers choose an adequate Nanotransfer vehicle.

Gene-vehicle integration

In a fast and simple step, gene and vehicle are mixed and integrated.

Therapy application

The system Gene-Vehicle is ready to be applied.

Pipeline

The team

We are a team with many years of experience in the field that gives us a real advantage to understand and design each one of the steps to optimize our delivery system.

Carla Giacomelli

CEO

Carla, combining strategic leadership and scientific expertise to pave the main road to ensuring Nanotransfer’s long-term viability.

LinkedIn

Cecilia Vasti

CSO

Cecilia leads the research and development team in exploring innovative technologies and products. Together with Carla, they create an operational roadmap aligned with the needs of the market.

LinkedIn

Julia Mattoni

COO

Julia has business acumen, driving business growth and scalability, while cultivating a collaborative, high-performance culture.

LinkedIn

In Nanotranfer we have the knowledge that let us develop a technology to impact the therapeutics market globally. Most importantly, we have the courage, ambition, passion and grit to make it possible.

Support us